Problem

Freed addresses the administrative burden of clinical documentation, where clinicians spend hours converting patient conversations into notes instead of focusing on care. The pain is both operational and economic: traditional documentation takes hours each day, while Freed’s pricing starts at $149 per month and its users report reclaiming roughly 5–15 hours per week—or about two hours per day. The core use case is turning a clinical visit into a finished note quickly enough to eliminate the documentation backlog and reduce clinician burnout.

Product / Service

Freed is a subscription-based AI healthcare assistant centered on an ambient medical scribe. It listens to patient-clinician conversations, transcribes them, and generates complete, specialty-aware clinical notes— including SOAP notes—about a minute after the visit. The product also supports decision support, coding, patient instructions, referral letters, and other workflow tasks, with browser-based EHR push integrations that let clinicians send notes into their existing systems.

The service is positioned for the broader care team rather than only physicians, extending across scribing, coding, front-desk work, and practice management. Its benefit is to reduce paperwork while preserving clinician attention for patients; Freed says its tools are designed to save time, and its plans include a free-trial path alongside paid subscriptions.

Market

Freed competes in the healthcare AI documentation and ambient medical scribe market, particularly among small and midsized clinics. Relevant competitors include Nuance DAX, Abridge, DeepScribe, and Heidi; Freed’s own comparison positions itself for small and midsized clinics while describing Nuance DAX and Abridge as particularly strong in Epic-centered hospital systems.

Freed is clearly commercial rather than pre-revenue. Its site reports more than 26,000 clinicians across more than 1,300 health organizations, while its careers page says the product is used by tens of thousands of clinicians daily and touches millions of patients monthly. The company raised a $30 million Series A led by Sequoia Capital in March 2025, and Sacra estimated $19 million in annual recurring revenue as of March 2025, although that revenue figure is a third-party estimate rather than an audited company disclosure.